Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.41 |
| ▸ | HMGCR | P04035 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 3/20 | 0.36 |
| ▸ | CES1 | P23141 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167623 | 1.00 | TSHR (0.44) | TSHRTHRBPTPN7HMGCRLMNA | |
| SCHEMBL15602923 | 1.00 | TSHR (0.44) | TSHRTHRBPTPN7HMGCRLMNA | |
| SCHEMBL10320432 | 1.00 | TSHR (0.44) | TSHRTHRBPTPN7HMGCRLMNA | |
| SCHEMBL10318507 | 1.00 | TSHR (0.44) | TSHRTHRBPTPN7HMGCRLMNA | |
| SCHEMBL141646 | 1.00 | TSHR (0.44) | TSHRTHRBPTPN7HMGCRLMNA | |
| SCHEMBL10318763 | 1.00 | TSHR (0.44) | TSHRTHRBPTPN7HMGCRLMNA | |
| SCHEMBL16673339 | 1.00 | TSHR (0.44) | TSHRTHRBPTPN7HMGCRLMNA | |
| SCHEMBL10320431 | 1.00 | TSHR (0.44) | TSHRTHRBPTPN7HMGCRLMNA | |
| SCHEMBL5972588 | 1.00 | TSHR (0.44) | TSHRTHRBPTPN7HMGCRLMNA | |
| SCHEMBL142047 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2868325-B1 | TRANSDERMAL CANCER ANTIGEN PEPTIDE PREPARATION | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-20150150975-A1 | TRANSDERMAL CANCER ANTIGEN PEPTIDE PREPARATION | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2868325-A1 | TRANSDERMAL CANCER ANTIGEN PEPTIDE PREPARATION | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150975-A1 | TRANSDERMAL CANCER ANTIGEN PEPTIDE PREPARATION | TAP1, TAP2, MICA | TSHR 1876/4885THRB 2727/4885PTPN7 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.